GMTs and GMFRs of anti-hemagglutinin antibodies for vaccine-matched seasonal influenza strains in adults in Part 1.
INFLUENZA A, INFLUENZA B
Hemagglutination inhibition GMTs with associated 95% CIs against seasonal influenza A strains (A/Wisconsin/588/2019[H1N1]pdm09 and A/Hong Kong/45/2019[H3N2]) or influenza B strains (B/Washington/02/2019 (B/Victoria lineage) and B/Phuket/3073/2013 (B/Yamagata lineage)) are shown at Day 1 (baseline) and Day 29 (28 days after vaccination) among participants At 28 days after vaccination (Day 29) in Part 2 of the trial, all dose levels of mRNA-1010 (25 µg, 50 µg, and 100 µg) elicited GMTs for influenza A (H1N1 and H3N2) strains across age groups that exceeded GMTs elicited by Afluria (Fig. 